查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1317918

体内 CRO 市场：按类型（非囓齿动物、囓齿动物）、按 GLP 类型（GLP 毒理学、非 GLP）、按适应症分类 - 2023-2030 年全球预测

In Vivo CRO Market by Type (Non-Rodent, Rodent), GLP Type (GLP Toxicology, Non-GLP), Indication - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球体内CRO市场将大幅成长，达到44.6617亿美元，年复合成长率为9.68%，到2030年将达到85.6651亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球In Vivo CRO市场至关重要。透过检验业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1. In Vivo CRO的全球市场规模和预测是多少？

2.在预测期内，COVID-19 对全球 In Vivo CRO 市场的阻碍因素和影响是什么？

3.在预测期内，全球体内CRO市场需要投资哪些产品/细分市场/用途/领域？

4.In Vivo CRO在全球市场的竞争策略为何？

5.全球In Vivo CRO市场的技术趋势和法律规范是什么？

6.全球In Vivo CRO市场主要厂商的市占率是多少？

7. 体内CRO适合进入全球市场的型态和策略倡议是什么？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 由于经济效益，外包服务的使用增加
      • 增加公共和私营部门对药物研究的投资
      • 越来越关註生物相似药和药物开发
    • 抑制因素
      • 与临床试验过程相关的高成本
    • 机会
      • 临床试验流程的全球化
      • 竞争製药领域正在申请专利
    • 任务
      • In vivo CRO品管问题
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章体内 CRO 市场：依类型

  • 介绍
  • 不囓齿动物
  • 囓齿动物
    • 老鼠
    • 小鼠或大鼠

第7章体内 CRO 市场：依 GLP 类型

  • 介绍
  • GLP毒理学
    • 公司内部
    • 外包
  • 非GLP
    • 公司内部
    • 外包

第8章体内 CRO 市场：依适应症分类

  • 介绍
  • 自体免疫/发炎状况
    • 大肠激躁症
    • 多发性硬化症
    • 骨关节炎
    • 类风湿性关节炎
  • 血癌
  • 中枢神经系统状况
    • ALS
    • 癫痫
    • 亨丁顿舞蹈症
    • 肌肉再生
    • 帕金森氏症
    • 中风
    • 创伤性脑损伤
  • 糖尿病
  • 肥胖
  • 肿瘤学
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
  • 固态肿瘤
    • 患者来源的异质骨移植
    • 类似型号
    • 异质骨移植

第9章北美及南美体内CRO市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区体内CRO市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲体内CRO市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-0D217D5AEECD

The Global In Vivo CRO Market is forecasted to grow significantly, with a projected USD 4,466.17 million in 2023 at a CAGR of 9.68% and expected to reach a staggering USD 8,566.51 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global In Vivo CRO Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global In Vivo CRO Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats. The Non-Rodent is projected to witness significant market share during forecast period.

Based on GLP Type, market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing. The Non-GLP is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington's Disease, Muscle Regeneration, Parkinson's Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft. The Pain management is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global In Vivo CRO Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global In Vivo CRO Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global In Vivo CRO Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global In Vivo CRO Market?

4. What is the competitive strategic window for opportunities in the Global In Vivo CRO Market?

5. What are the technology trends and regulatory frameworks in the Global In Vivo CRO Market?

6. What is the market share of the leading vendors in the Global In Vivo CRO Market?

7. What modes and strategic moves are considered suitable for entering the Global In Vivo CRO Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. In Vivo CRO Market, by Type, 2022 vs 2030
  • 4.3. In Vivo CRO Market, by GLP Type, 2022 vs 2030
  • 4.4. In Vivo CRO Market, by Indication, 2022 vs 2030
  • 4.5. In Vivo CRO Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of outsourcing services due to economic benefits
      • 5.1.1.2. Growing investments in the pharmaceutical research by public and private sectors
      • 5.1.1.3. Rising focus on the development of biosimilar medicines and drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the clinical trial processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Globalization of clinical trial processes
      • 5.1.3.2. Competitive landscape in the pharmaceutical sector with patent applications
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to quality control in In vivo CROs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. In Vivo CRO Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Rodent
  • 6.3. Rodent
    • 6.3.1. Mice
    • 6.3.2. Rats

7. In Vivo CRO Market, by GLP Type

  • 7.1. Introduction
  • 7.2. GLP Toxicology
    • 7.2.1. In House
    • 7.2.2. Outsourcing
  • 7.3. Non-GLP
    • 7.3.1. In House
    • 7.3.2. Outsourcing

8. In Vivo CRO Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/inflammation conditions
    • 8.2.1. Irritable Bowel Syndrome
    • 8.2.2. Multiple Sclerosis
    • 8.2.3. Osteoarthritis
    • 8.2.4. Rheumatoid Arthritis
  • 8.3. Blood Cancer
  • 8.4. CNS conditions
    • 8.4.1. ALS
    • 8.4.2. Epilepsy
    • 8.4.3. Huntington's Disease
    • 8.4.4. Muscle Regeneration
    • 8.4.5. Parkinson's Disease
    • 8.4.6. Stroke
    • 8.4.7. Traumatic Brain Injury
  • 8.5. Diabetes
  • 8.6. Obesity
  • 8.7. Oncology
  • 8.8. Pain management
    • 8.8.1. Acute Pain
    • 8.8.2. Chronic Pain
  • 8.9. Solid Tumor
    • 8.9.1. Patient-derived Xenograft
    • 8.9.2. Syngeneic Model
    • 8.9.3. Xenograft

9. Americas In Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific In Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa In Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. IN VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. IN VIVO CRO MARKET SIZE, 2022 VS 2030
  • FIGURE 3. IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2030 (%)
  • FIGURE 6. IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 7. IN VIVO CRO MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. IN VIVO CRO MARKET DYNAMICS
  • FIGURE 9. IN VIVO CRO MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. IN VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 7. IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. IN VIVO CRO MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IN VIVO CRO MARKET SIZE, BY RATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 16. IN VIVO CRO MARKET SIZE, BY NON-GLP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 21. IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 28. IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. IN VIVO CRO MARKET SIZE, BY ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. IN VIVO CRO MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. IN VIVO CRO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. IN VIVO CRO MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 44. IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 354. POLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 362. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 363. QATAR IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 364. QATAR IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. QATAR IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 366. QATAR IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 368. QATAR IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 369. QATAR IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 370. QATAR IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 371. QATAR IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 372. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 373. RUSSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 374. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 375. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 376. RUSSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 377. RUSSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 378. RUSSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 379. RUSSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 380. RUSSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 381. RUSSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 382. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (